1. Practical Asymmetric Synthesis of Efavirenz (DMP 266), an HIV-1 Reverse Transcriptase Inhibitor
- Author
-
Andrew S. Thompson, Richard D. Tillyer, Dalian Zhao, Anusuya Choudhury, Lushi Tan, Edward G. Corley, Lisa F. Frey, Lilian A. Radesca, Edward J. J. Grabowski, Cheng-yi Chen, Dieu Nguyen, Joseph M. Fortunak, Stuart Silverman, Michael E. Pierce, Susan J. Morgan, Young S. Lo, Chi Luo, Robert A. Reamer, Paul J. Reider, Feng Xu, James R. Moore, Rodney L. Parsons, Q. Islam, Pat N. Confalone, and Wayne P. Davis
- Subjects
Efavirenz ,Reverse-transcriptase inhibitor ,Stereochemistry ,Acetylide ,Organic Chemistry ,Enantioselective synthesis ,Stereocenter ,chemistry.chemical_compound ,chemistry ,Yield (chemistry) ,Alkoxide ,medicine ,Enantiomeric excess ,medicine.drug - Abstract
A highly enantioselective and practical synthesis of the HIV-1 reverse transcriptase inhibitor efavirenz (1) is described. The synthesis proceeds in 62% overall yield in seven steps from 4-chloroaniline (6) to give efavirenz (1) in excellent chemical and optical purity. A novel, enantioselective addition of Li-cyclopropyl acetylide (4a) to p-methoxybenzyl-protected ketoaniline 3a mediated by (1R,2S)-N-pyrrolidinylnorephedrine lithium alkoxide (5a) establishes the stereogenic center in the target with a remarkable level of stereocontrol.
- Published
- 1998
- Full Text
- View/download PDF